In contrast, to optimize the antitumor activity, current research efforts aim at the discovery of Top2α-specific poisons, which are expected to not induce cardiomyopathies and secondary cancers, likely due to the Top2β. This evidence concerns the gene TOP2A and cardiomyopathy.